Active	Status	Sponsor type	Region	Phase	Filter
7 Active 10 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Powell, Bayard L
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation	Completed	3	56	US	ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	06/23	06/24
NCT05854966: CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Withdrawn	2	17	NA	CPI 613, Devimistat, Metformin, Metformin pill, Blood draws, Bone marrow biopsy	Wake Forest University Health Sciences, National Cancer Institute (NCI), Cornerstone Pharmaceuticals	Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma	04/25	09/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Active, not recruiting	2	196	US	asciminib, ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	09/25	10/27